Pump.fun: Can $1.8mln whale buying help PUMP target $0.0022?

ambcryptoPublished on 2026-03-02Last updated on 2026-03-02

Abstract

PUMP rebounded from $0.0016 to a local high near $0.0019, but remained below the $0.002 threshold. A newly created whale wallet accumulated 947.31 million PUMP tokens worth $1.86 million over two days, signaling confidence. Top addresses added 4.3 billion tokens in 24 hours, and the team spent $1.2 million on buybacks. However, the market faces significant selling pressure, with a negative Buy Sell Delta of -500 million and the Stochastic Momentum Index in the negative zone. If whale demand helps PUMP above $0.0019, it could target $0.0022; otherwise, it risks falling back to $0.0016.

Since reaching $0.0016, Pump.fun has shown upward momentum, reaching a local high of $0.0019. In fact, the altcoin, as of this writing, Pump.fun [PUMP] traded at $0.001906, down 3.02% on the daily charts.

Pump.fun whale scoops up 947 million PUMP tokens

With PUMP holding below $0.002, it has created a perfect buying opportunity for large entities, especially whales.

According to Lookonchain, a newly created wallet purchased 947.31 million PUMP worth $1.86 million. This whale has been on a buying spree for the past two days.

Usually, when a whale enters the market to accumulate during a period of weakness, it shows confidence, anticipating market recovery.

Significantly, this whale purchase is not an isolated case, as large holders have been aggressively accumulating. According to Nansen data, Top Addresses added 4.3 billion PUMP tokens over the past 24 hours.

Historically, increased whale accumulation has strengthened an asset’s upside momentum, leading to higher prices. Thus, if Pump.fun whales continue buying, the demand-side liquidity could help PUMP break out of the current bearish trap.

Coupled with that, the team has continued to pivot the market, absorbing the market pressure through buybacks. Over the past 24 hours, Pump.fun spent 99% of the daily revenue, or $1.2 million, and purchased 15.011 PUMP tokens.

The team’s continued buybacks show its commitment to the asset, which helps boost demand-side pressure, a key driver of price recovery.

Downside risk still remains elevated

While whales continue to accumulate, other market participants have shown a tendency to cash out even slight gains. On March 2, the altcoin saw 1.7 billion in Spot Sell Volume compared to 1.2 billion in Buy Volume.

This imbalance left the market with a negative Buy Sell Delta of -500 million, a clear sign of aggressive Spot selling. Often, increased selling pressure from the spot market accelerates downside momentum.

In fact, the altcoin’s downside momentum continues to hold the market strongly, as evidenced by the Stochastic Momentum Index (SMI). Looking at the indicator, it still sits within the negative zone, suggesting that sellers have total control of the market.

As such, while buyers, especially whales, have attempted to absorb pressure, their demand remains insignificant to lift PUMP from the prevailing trend.

Thus, the continuity of the prevailing sentiment could see PUMP drop towards $0.0016 again. However, if the whale demand helps the altcoin close above $0.0019, it will be strong enough to target $0.0022.


Final Summary

  • PUMP rebounded from $0.0016 to a local high near $0.0019, but remained below the $0.002 threshold.
  • A newly created wallet accumulated 947.31 million PUMP worth $1.86 million over two days.

Related Questions

QWhat was the price of Pump.fun (PUMP) at the time of writing, and what was its daily change?

AAt the time of writing, Pump.fun (PUMP) traded at $0.001906, down 3.02% on the daily charts.

QHow many PUMP tokens did a whale purchase, and what was the total value of that transaction?

AA whale purchased 947.31 million PUMP tokens, worth a total of $1.86 million.

QAccording to Nansen data, how many PUMP tokens did Top Addresses add in the 24-hour period mentioned?

AAccording to Nansen data, Top Addresses added 4.3 billion PUMP tokens over the past 24 hours.

QWhat was the Buy Sell Delta for PUMP on March 2nd, and what does this indicate about market activity?

AOn March 2nd, the Buy Sell Delta for PUMP was -500 million, indicating aggressive spot selling pressure as sell volume (1.7B) exceeded buy volume (1.2B).

QWhat are the two potential price targets for PUMP mentioned in the article, and what condition is required to reach the higher target?

AThe two potential price targets are a drop to $0.0016 or a rise to $0.0022. To target $0.0022, the altcoin needs to close above $0.0019 with the help of whale demand.

Related Reads

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

On August 18th, Haowei Huaxin, a semiconductor firm specializing in gallium arsenide and gallium nitride wafers, reported that over a hundred individuals forcibly entered its offices and seized the company's official seals from a safe, including the corporate, contract, and party committee seals. The incident is the latest escalation in a protracted control dispute. Haowei Huaxin, established in 2010, was originally a joint venture. Control became contested after 2021 when Zhenwei Financial Holding injected capital, becoming the largest shareholder (34.01%), while former parent Haite High-Tech's stake was diluted to 33.79%. An agreed-upon governance structure collapsed, leading to mutual accusations. Haite claimed it was locked out of the subsidiary's premises, while also alleging improper management like livestock being kept on the chip fabrication site. After state-owned Qingdao Haiyue Holdings took over Zhenwei's stake in 2023, Haite accused it of illegally seizing control. Despite Haite winning several legal battles in 2024-2026, which affirmed its rights to nominate directors and the chairman, it failed to regain physical control or recover the seals. The stakes are high: market valuations for Haite's stake in Haowei Huaxin are estimated between 3.7 to 5 billion USD, yet it is only valued at about 83 million USD on Haite's books. Losing control effectively jeopardizes a significant portion of Haite's value. In response to the seal seizure, Haite framed it as a "shareholder rights protection" action agreed upon by five shareholders. This mirrors a pattern in Chinese corporate disputes where seizing physical seals becomes a tactic to paralyze the opponent's daily operations, seen in past conflicts at companies like Dangdang and Bitmain. However, such actions don't resolve underlying ownership issues; the opposing party can report the seals stolen, declare them void, and apply for new ones, albeit with significant delay. The incident underscores how fragile corporate governance can devolve into physical confrontations over symbols of authority, with control ultimately determined by law and shareholding, not possession of a seal.

marsbit38m ago

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

marsbit38m ago

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

Bernstein's analysis of Moderna's 177% stock surge following positive Phase 3 results for its individualized neoantigen therapy (INT) in melanoma distinguishes fundamental drivers from market speculation. The clinical breakthrough is real: the INTerpath-001 trial met its primary and key secondary endpoints, providing crucial validation for mRNA technology in oncology beyond infectious diseases. However, Bernstein argues the magnitude of the stock move cannot be justified by this single trial's fundamentals alone. The surge was amplified by three key factors: 1) A re-rating of Moderna's mRNA platform potential for expansion into other cancers, 2) A massive short squeeze, given ~15% of shares were sold short pre-announcement, and 3) The compelling "cancer vaccine" narrative that fueled broader investor enthusiasm. While the melanoma success is significant, Bernstein cautions that replication in lung, kidney, and bladder cancers—which have different immunogenicity—is not guaranteed. Furthermore, INT's commercial model faces challenges: it's a personalized treatment, not a mass-market vaccine, implying higher production costs and potential margin pressures despite a projected multi-billion dollar peak sales opportunity. The report also notes sector rotation, with some funds moving from crowded AI/semiconductor trades into defensive healthcare stocks, adding further momentum. In conclusion, Bernstein maintains a "Market-Perform" rating and a $45 price target, far below the post-surge price. It views the current valuation as pricing in an optimistic multi-cancer platform success and efficient commercialization that are yet to be proven. The clinical inflection point is clear, but the earnings inflection point awaits validation across future trials and commercial execution.

marsbit38m ago

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

marsbit38m ago

Trading

Spot
活动图片